1:25cv1072 • February 6, 2025
Class Period Start
September 15, 2023
Class Period End
February 6, 2025
PSLRA Deadline
April 7, 2025
Case Allegations
Sec11
Statutes of Repose
Sep 15, 2026
Country
United States
Court
Federal Court
Jun 15, 2026
After reviewing the complaint(s) filed by plaintiffs, defendants have filed a motion requesting that the court dismiss some or all of the plaintiffs' claims. In a motion to dismiss, defendants might challenge the validity of plaintiffs' claims or adequacy of plaintiffs' pleadings. Once a motion to dismiss is filed, the judge will make a decision on whether part or all of the case should be dismissed or the case can proceed as alleged.
May 5, 2026
A new complaint has been filed on behalf of certain investors in Neumora Therapeutics, Inc.. Amended complaints may contain additional facts, parties, allegations, a change in the class definition, etc.
May 5, 2026
The court has denied the defendants' request to dismiss the lawsuit. The case can now move forward to the next stage of litigation.
Mar 11, 2026
After reviewing the complaint(s) filed by plaintiffs, defendants have filed a motion requesting that the court dismiss some or all of the plaintiffs' claims. In a motion to dismiss, defendants might challenge the validity of plaintiffs' claims or adequacy of plaintiffs' pleadings. Once a motion to dismiss is filed, the judge will make a decision on whether part or all of the case should be dismissed or the case can proceed as alleged.
Jan 14, 2026
A new complaint has been filed on behalf of certain investors in Neumora Therapeutics, Inc.. Amended complaints may contain additional facts, parties, allegations, a change in the class definition, etc.
Nov 19, 2025
The court has appointed a lead plaintiff to represent the interests of investors in the lawsuit. The lead plaintiff works with the attorneys handling the case, helps oversee the litigation, and represents the interests of the proposed class.
Feb 6, 2025
A securities fraud class action complaint has been filed on behalf of certain investors in Neumora Therapeutics, Inc..
TOP
